OUR LEADERSHIP
… is focused on delivering solutions for the advancement of human health. Founded on science, driven by passion, and guided by meritocracy, it will shape the development and acceptance of patient-friendly medicines.
OUR MANAGEMENT TEAM
… stewards for impact and transformative societal change guided by the spirit of innovation, principles of governance, with servitude to patients, shareholders and stakeholders.
Ahmad Doroudian, PhD
Chief Executive Officer & Director
- 20+ years experience as a Pharma CEO in finance, including M&A, and multiple IPOs, integration of pharmaceutical operations (Whitehall Robbins, Rhone Polenc, Boehringer, Aventis)
- Founder of Merus Labs (NASDAQ: MSLI), sold for $300 M+ in 2017
- Acquisition, integration, tech transfer and management of branded pharmaceutical products Enablex®/Emselex®, Entrophen®, Sandomigran®, Sintrom®, Vancocin®, Zaditen®
Hooshmand Sheshbaradaran, PhD
Chief Operating Officer
- 30+ years senior pharma executive with experience in global drug development, marketing, business strategy, operations, licensing and M&A
- Senior executive roles at Pharmacia/Pfizer, Roche, Zeneus/Cephalon, Niiki Pharma, Psioxus
- Development of Camptosar®, Ellence®, Emcyt®, Sutent® and Vidaza®.
Moira Ong, CPA, CA
Chief Financial Officer
- 20+ years experience in financial reporting, compliance and audit.
- Managed the integration of the supply chain management and accounting for Vancocin, Enablex®/Emselex®, acquired from Novartis, by Merus Labs International Inc. (formerly NASDAQ: MSLI)
- Previously at Grant Thornton, Deloitte & Touche
Scott Rudge, PhD
Head CMC
- Founded CMC development expert services group in 2004, has worked on over 200 projects for all molecule/therapy classes since
- Site Director & VP Operations for FeRx; increasing management responsibility at NIST, Synergen, Amylin
- PhD in Chemical Engineering from Purdue and author of multiple peer reviewed articles, book chapters and an award-winning textbook
Abdi Ghaffari, PhD
Head Preclinical & Toxicology
- 15+ years pharma executives with experience in nonclinical pharmacology and toxicology in fields of neuropsychiatric disorders, oncology, and respiratory infection.
- Senior scientist roles at PulmoNOx, Beyond Air, Novateur, and Tika Therapeutics.
OUR SCIENTIFIC ADVISORS / COLLABORATORS
… work with thorough multi-disciplinary skill sets, as the vanguard to create, develop, test and advance discoveries for the needed solutions.
OUR BOARD OF DIRECTORS
… brings accomplished, diverse, noble, and fostered set of experiences important to effect change with prudency, purpose, and passion while managing challenges.
Ahmad Doroudian, PhD
- 20+ years experience as a Pharma CEO in finance, including M&A, and multiple IPOs, Integration of pharmaceutical operations (Whitehall Robbins, Rhone Polenc, Boehringer, Aventis)
- Founder of Merus Labs (NASDAQ: MSLI), sold for $300 M+ in 2017
- Acquisition, integration, tech transfer and management of branded pharmaceutical products Enablex®/Emselex®, Entrophen®, Sandomigran®, Sintrom®, Vancocin®, Zaditen®
Robert Metcalfe
- Served as president, chief executive officer, lead director, chairman and committee member on numerous publicly listed natural resource and industry company corporate boards in Canada, the USA, England, South America and Africa
- Senior partner with the law firm, Lang Michener LLP, for 20 years
- Engaged in numerous acquisitions, divestitures, corporate reorganizations, financings and corporate improvements, as well as serving on numerous special committees across many sectors
Ralph Anthony Pullen
- Investment banker in the healthcare and biotechnology industry sectors
- Instrumental in the creation and funding of MDS Capital Corp., Canada’s largest venture capital fund dedicated to the life sciences, now known as Lumira Capital where he served as a board member
Dr. Steven Sangha
- 25+ years of experience in investment banking, business development and asset management.
- Extensive experience with public company governance, compliance and finance has led Dr. Sangha to run a successful private fund family office.
- Interest in the biotechnology and mining industries has allowed positive growth for early-stage companies with Dr. Sangha’s consummate efforts in assessment, development and financial support.
- Doctorate of Dental Surgery (University of Western Ontario, London, Ontario) and a Bachelor of Pharmaceutical Science (University of British Columbia, Vancouver, British Columbia).
André Beaudry
- Led teams in Canada, China, England, India and the Philippines, and collaborated with industry, education, government and philanthropic leaders to secure over $140M for a variety of initiatives, including mental health.
- Founder of Velocity Collaboration Corporation.
